Medical Device & Technology Editorial Staff

Osteoboost is the first non-pharmacological therapy approved to treat low bone density in postmenopausal women.

Tumor-treating fields therapy uses alternating electric fields of intermediate frequency and low intensity to disrupt processes critical in the survival of cancer cells.

Axon Therapy uses magnetic peripheral nerve stimulation to deliver a non-invasive treatment for chronic pain related to nerve damage caused by diabetes.

Biologics license application filed for 89Zr-DFO-girentuximab (TLX250-CDx; Zircaix), a PET imaging agent for clear cell renal cell carcinoma.

Highlights of the year’s biggest news.

Patients with the HeartMate 3 heart pump for advanced heart failure not taking aspirin as part of their blood-thinning medication regimen had fewer complications from bleeding with lower hospital visits.

Removable Complete Airway Repositioning and/or Expansion oral appliances are indicated for adults with severe obstructive sleep apnea.

Roche's Elecsys HBeAg quant is an immunoassay able to determine the presence and quantity of the hepatitis B e antigen in human serum and plasma.

PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.

The Elecsys NfL test is designed to aid in detecting disease activity and to offer insights in disease management for patients with multiple sclerosis.

The newly approved Alinity m high risk human papillomavirus (HPV) assay is indicated to detect HPV and for use in routine cervical cancer screening per professional medical guidelines.

The continued development of more convenient VR technology has improved usability, accessibility, and affordability across healthcare settings.